How Leclerc & Co. Is Redefining Affordable Luxury in the Watch Industry
WAN CHAI, HONG KONG / ACCESS Newswire / June 28, 2025 / Leclerc & Co, a rising direct-to-consumer watch brand, is setting a new standard for what it means to own a luxury piece without paying five figures - or compromising identity.
Founded with a mission to blend timeless watch designs with strategic scarcity, Leclerc & Co has built a loyal fanbase among those who crave refinement without the noise. The brand's limited releases and signature design language echo the presence of old-money elegance - but with accessibility in mind.
A spokesperson from the brand shared: 'We create exclusive pieces that people are going to admire on your wrist. We define exclusivity not by inflated price tags, but by intentional scarcity. Our pieces are designed to be affordable - but only a few will ever truly own them.'
At the core of Leclerc's rise is a radical shift in how luxury is defined. Leclerc anchors its appeal in authenticity - tight inventory, no excessive branding, and a sharp focus on what actually matters: design, experience, and emotional connection. Each launch is handled like a private release - often selling out within days.
Authentic Leclerc & Co pieces are only available through the brand's official website, a move that allows the company to maintain strict control over quality, pricing, and the customer experience - while preserving the brand's air of exclusivity.
Discover 'The Date' - Leclerc's Signature Limited Release
The latest drop, The Date Collection, represents everything the brand stands for: classic design, everyday elegance, and uncompromising quality.
Each dial color is strictly limited to 100 pieces worldwide, reinforcing the idea that true luxury isn't mass-produced - it's quietly owned.
Explore the full collection here:
https://leclercwatches.com/collections/date
Each Leclerc & Co timepiece is hand-polished, meticulously finished, and authenticated with a certificate of provenance.
This balance of understated status and affordable pricing is what sets Leclerc apart from the sea of 'affordable luxury' brands.
Visit their official website here: https://leclercwatches.com
Leclerc & Co International
2301, 23/f Bayfield Bldg 99 Hennessy Rd Wan Chai Hong Kong
[email protected]
https://leclercwatches.com
Contact Person: Louis Leclerc
SOURCE: Leclerc & Co
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Trump calls leaders of Thailand and Cambodia to push for a ceasefire
President Donald Trump said Saturday that he had called the leaders of Cambodia and Thailand to urge them to reach a ceasefire, suggesting that if their deadly border conflict continues, he would hit both countries with heavy tariffs on Aug. 1. The three-day-long clash between the two countries has been escalating, with more than 30 dead, thousands displaced and troops massing on both sides of the border, prompting growing concern from global leaders. Each country blames the other for starting the conflict and says it is acting in self defense. Trump said on Truth Social that he had spoken with both Cambodian Prime Minister Hun Manet and Phumtham Wechayachai, Thailand's acting leader, to urge an end to the skirmish. The United States is engaged in trade talks with Thailand and Cambodia, he noted, but he could cease those negotiations. 'We happen to be, by coincidence, currently dealing on Trade with both Countries, but do not want to make any Deal, with either Country, if they are fighting — And I have told them so!' Trump posted. In a separate post, he said he had a 'good conversation' with the Thai leader. 'After speaking to both Parties, Ceasefire, Peace, and Prosperity seems to be a natural. We will soon see!' he wrote. He also suggested that his administration was adept at handling international conflicts. 'I am trying to simplify a complex situation! Many people are being killed in this War, but it very much reminds me of the Conflict between Pakistan and India, which was brought to a successful halt,' he added. Trump's mention of India and Pakistan referred to a U.S.-brokered ceasefire between those two countries that was reached in early May after several days of heavy fighting broke out. That ceasefire was reached after Secretary of State Marco Rubio engaged in intensive shuttle diplomacy between Indian and Pakistani leaders. The president's latest pronouncements were another reflection of the way he is wielding the threat of tariffs to push other nations to bend to his preferences on issues beyond trade. Imports from Thailand and Cambodia are slated to face among the Trump administration's heaviest levies, 36 percent, if the countries do not reach a trade deal with the U.S. by Aug. 1. Trump made his announcement Saturday while visiting Scotland to play golf at his course in Turnberry, a trip that has attracted both supporters and protesters. His public intervention in the Thailand-Cambodia conflict raises pressure on the two countries, but the outcome is far from clear. Cambodia called for an 'immediate ceasefire' on Friday. But Thai officials have tempered their response. Thailand 'agrees in principle to have a ceasefire in place,' Phumtham, the acting Thai prime minister, posted on Facebook on Saturday after Trump's announcement. 'However, Thailand would like to see sincere intention from the Cambodian side.' Thai Foreign Minister Maris Sangiampongsa also said Saturday that Cambodia must be the first to suspend hostilities since Thailand accuses Cambodia of initiating the conflict. Sangiampongsa earlier turned down the prospect of third-party mediation, saying that negotiations must be bilateral. In three days of fighting, the clashes have killed at least 33 people. Thirteen Cambodians and 20 Thais have died, according to the Associated Press, and most of those killed have been civilians. The conflict has caused wide disruption in the area, and more than 168,000 people living near the border have been displaced. Cambodian Information Minister Neth Pheaktra said Saturday that 37,635 Cambodians were forced to relocate. About 131,000 people on the Thai side have also fled their homes, and Thailand has declared martial law in eight border districts.
Yahoo
2 hours ago
- Yahoo
Pharma sector outlook as Trump's drug tariff deadline looms
Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca's (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. Pharmaceutical stocks in focus as we approach President Trump's looming drug tariff deadline. For more, I want to bring in Yahoo Finance senior health reporter Angelique Chenge. That's right, Josh. With that looming deadline, potentially August 1st, for up to 200% in tariffs, we don't know what that number will actually end up being. We've heard from several companies that have announced manufacturing commitments in hopes to thwart that effort. That includes AstraZeneca. We spoke to CEO Pascal Soriot about that, and he did mention that the announcement for $50 billion, that's in addition to $3.5 billion last year, is in part a response to Trump's tariffs. We know others like Eli Lilly and Johnson & Johnson have also announced similarly big announcements of commitments for manufacturing. And this is in play at a time where the industry is also going through a bit of tumult. We know that there is a lot of investment in one of Trump's least favorite countries, that is China. That is the reason why there has been a lot of tension in the biotech world. We also know that big pharma has been pivoting and investing there as well. Licensing deals and the like are on the rise as they look to sort of respond to all the different countries that are looking for what has now been termed health sovereignty. And this plays into that. So, when I asked Pascal about that, about China and the deal making there, here's what he had to say about it. We believe that it's our ethical responsibility to bring medicines to as many people as possible. Of course, there are limitations to what we can do, but we work very hard to do this. And we are lucky enough or good enough or both, that we are growing. And growth brings opportunities. And because we are growing, we are able to invest in United States for the United States, we're able to invest in China for China, and we're also able to seek innovation where it happens. Because actually, if innovation happens in China or in Europe, we need to take this innovation, develop it, and bring it to patients for instance in the United States, but manufacture the product in the United States. Um, and I think that brings me to an important point that people don't talk enough about is that today innovation in our industry takes place in the U.S. U.S. is the biggest innovator for biopharmaceuticals. And it's really important that everything is done to protect that innovation. It's a fantastic engine to bring new medicines to patients but also create good jobs, well-paid jobs, and economic growth. So, as you can hear, a lot of focus on that, on economic growth being the driver as well and needing to respond to these countries and their efforts. AstraZeneca also talked about how it would help shift revenues for the portfolio with a greater reliance on the U.S. Currently, 42% of revenues comes from the U.S. And with this increase in manufacturing, it would be 50%. And that includes GLP-1s. We know that there's a lot of global demand for that drug and for those types of drugs. AstraZeneca has been pursuing an oral form or pill form, which is largely seen as the next frontier in this space. AstraZeneca looking at being able to then supply the rest of the world from the U.S., making it a larger exporter. So, here's what Pascal said about that. It's also a reason, another reason why we are investing in this very large facility. We have our oral GLP-1. Everybody knows GLP-1 by now. These are agents used to help people manage their weight. We have an oral agent, and we have bet on oral agents because we think they are going to be easier for patients, because they will be cheaper, they'll be more accessible, and we will be able to export them around the world, not only supply America. But we also have other products treating cardiovascular metabolic disease. We have a new agent for hypertension for patients who are not controlled on multi-medicines. We have an oral PCSK9 for the control of cholesterol and many others. Cardiovascular metabolic diseases are the biggest killer in the world today, including in the United States. So, you can see the needs are enormous. This plant will supply products for American patients, so American patients will access products that are American-made. But this plant will also export to the billions of patients around the world who need these medicines. The company really moving that pot of money, you know, globally and looking at where it makes the most sense. Pascal also did tell me that in looking at the different areas of the world where the money can be, you know, invested, China, of course, being one of them. And then if you compare the amount that has been put in there, that is $5.3 billion is one of the latest deals that AstraZeneca has done in China. And if you compare that to the $50 billion, while not on the same level, you can still see it's quite a large number. And that's just one of those deals. So, we're starting to see a little bit of bifurcation in how the global pharmaceutical economy is functioning. Related Videos Uncertainty is 'here to stay': What that means for markets BlackRock's Rick Rieder: I Think Rates Can Come Down Elon Musk's 'master plan': Is Tesla an EV maker or AI play? 'We ask for more data' than FICO: VantageScore CEO Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
These Old Coins and Banknotes Are Selling For More Than Real Estate
Some old coins and banknotes are selling for more than the cost of a home. These collectibles are drawing six-figure bids from buyers, pushing them into the same conversation as traditional investments like real estate. The right item, authenticated and auctioned, can deliver an outsized return, all without the maintenance, taxes or paperwork that come with owning property. Check Out: Read Next: Kuang-Hsü Tael (1906) In June 2025, a rare Chinese silver coin called the Kuang-hsü Tael from the Peh Family Collection sold for $810,000 at a Heritage Auctions event, according to CoinWeek. It's a coin few people have ever held in person, but collectors were willing to pay more than the average home price in cities like Austin ($523,769), Denver ($555,304) and Salt Lake City ($571,623). More Collectibles: Long-Whiskered Dragon Dollars (1911) The Peh Family Collection also produced two highly sought-after 1911 'Long-Whiskered Dragon' silver dollars that set auction records. A 'Restrike Specimen Pattern Long-Whiskered Dragon Dollar Year 3' (1911) graded SP63 by NGC sold for $504,000, while a nearly identical piece, graded SP63+, went for $408,000 — both fetching more than the average home price in Tucson ($331,789) or Jacksonville ($290,108). Netherlands Bank 100 Gulden Note (1814-1838) At the same auction, a Dutch banknote fetched $114,000. It wasn't gold, and it wasn't flashy, but it was rare and in great condition. For perspective, that single piece of paper sold for more than the average home in Detroit ($78,601). Why Collectibles Are Beating Property A decent home in a mid-sized city might take 90 days or more to sell. The seller covers taxes, agent commissions, repairs and closing costs. And unless it's in a booming market, the return often creeps up slowly, if at all. Compare that to the collectibles market. A coin can be shipped to an auction house, authenticated and sold to a global bidder base in days. No yard signs or home inspections, and a rare item in pristine condition can get instant interest and a fast sale. And while real estate is often limited by location, collectibles aren't. A coin stored in a desk drawer in New Jersey can sell to a buyer in Tokyo or Dubai without ever changing hands physically. That kind of mobility and liquidity makes coins and notes increasingly attractive, especially when markets are uncertain. Editor's note: Average home prices were sourced from More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard The 10 Most Reliable SUVs of 2025 How Far $750K Plus Social Security Goes in Retirement in Every US Region This article originally appeared on These Old Coins and Banknotes Are Selling For More Than Real Estate Sign in to access your portfolio
